Bank of Montreal Can Raises Position in RxSight, Inc. (NASDAQ:RXST)

Bank of Montreal Can grew its position in shares of RxSight, Inc. (NASDAQ:RXST) by 32.4% during the third quarter, according to its most recent filing with the SEC. The firm owned 119,580 shares of the company’s stock after acquiring an additional 29,230 shares during the period. Bank of Montreal Can owned about 0.30% of RxSight worth $5,804,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Brown Capital Management LLC bought a new stake in RxSight in the third quarter worth $26,813,000. Marshall Wace LLP purchased a new stake in RxSight during the 2nd quarter valued at about $19,512,000. Driehaus Capital Management LLC grew its position in RxSight by 74.9% during the 2nd quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock valued at $42,490,000 after purchasing an additional 302,367 shares during the last quarter. Baillie Gifford & Co. raised its holdings in RxSight by 438.8% in the second quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock worth $21,554,000 after buying an additional 291,733 shares during the last quarter. Finally, William Blair Investment Management LLC bought a new stake in shares of RxSight during the 2nd quarter valued at $14,942,000. Institutional investors own 78.78% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Stifel Nicolaus dropped their price target on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Oppenheimer cut their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research note on Tuesday, August 6th. Jefferies Financial Group started coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Finally, Wells Fargo & Company decreased their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $61.63.

RxSight Stock Performance

NASDAQ RXST opened at $45.84 on Tuesday. The firm’s 50 day moving average price is $48.58 and its 200-day moving average price is $52.17. RxSight, Inc. has a 52-week low of $29.97 and a 52-week high of $66.54. The company has a market cap of $1.85 billion, a PE ratio of -55.28 and a beta of 1.19.

Insider Activity

In other RxSight news, Director Jesse Anderson Corley purchased 11,111 shares of the stock in a transaction on Tuesday, November 12th. The shares were bought at an average price of $45.37 per share, for a total transaction of $504,106.07. Following the completion of the transaction, the director now owns 468,571 shares of the company’s stock, valued at $21,259,066.27. This trade represents a 2.43 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Ilya Goldshleger sold 3,100 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $53.19, for a total value of $164,889.00. Following the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at approximately $2,247,064.74. The trade was a 6.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,702 shares of company stock valued at $3,059,197 in the last ninety days. Insiders own 9.36% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.